TABLE 1. Summary of pruritusa in a noncirrhotic NASH Phase 2 study.
CILO 100 mg (n = 56) | CILO 30 mg (n = 56) | PBO (n = 28) | |
---|---|---|---|
Grade 1, n (%) | 8 (14) | 10 (18) | 5 (18) |
Grade 2, n (%) | 7 (13) | 1 (2) | 0 |
Grade 3, n (%) | 1 (2) | 0 | 0 |
Any Grade, n (%) | 16 (29) | 11 (20) | 5 (18) |
Abbreviations: CILO, cilofexor; PBO, placebo.
Pruritus and pruritus generalized in the adverse event list.